Regeneron seeks marketing clearance in EU for Eylea injection in BRVO

Regeneron Pharmaceuticals and Bayer HealthCare have applied to the European Medicines Agency to obtain marketing authorization in the European Union for Eylea in the treatment of macular edema associated with branch retinal vein occlusion, according to a press release.The application is based on the VIBRANT trial, a phase 3 controlled, randomized study of patients with macular edema following BRVO.